Precision BioSciences, Inc. (DTIL): Price and Financial Metrics


Precision BioSciences, Inc. (DTIL)

Today's Latest Price: $6.45 USD

0.04 (-0.62%)

Updated Oct 27 6:55pm

Add DTIL to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

DTIL Stock Summary

  • DTIL's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.21 -- higher than merely 4.06% of US-listed equities with positive expected earnings growth.
  • Precision Biosciences Inc's stock had its IPO on March 28, 2019, making it an older stock than only 2.55% of US equities in our set.
  • DTIL's price/sales ratio is 17.45; that's higher than the P/S ratio of 91.27% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Precision Biosciences Inc are JNCE, MGEN, FULC, SRRK, and RCUS.
  • Visit DTIL's SEC page to see the company's official filings. To visit the company's web site, go to www.precisionbiosciences.com.

DTIL Stock Price Chart Interactive Chart >

Price chart for DTIL

DTIL Price/Volume Stats

Current price $6.45 52-week high $23.67
Prev. close $6.49 52-week low $4.45
Day low $6.30 Volume 208,500
Day high $6.53 Avg. volume 613,732
50-day MA $6.06 Dividend yield N/A
200-day MA $7.20 Market Cap 337.63M

Precision BioSciences, Inc. (DTIL) Company Bio


Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.


DTIL Latest News Stream


Event/Time News Detail
Loading, please wait...

DTIL Latest Social Stream


Loading social stream, please wait...

View Full DTIL Social Stream

Latest DTIL News From Around the Web

Below are the latest news stories about Precision Biosciences Inc that investors may wish to consider to help them evaluate DTIL as an investment opportunity.

Precision Bio CAR T candidate Fast Track'd for multiple myeloma

The FDA designates Precision BioSciences' (DTIL) PBCAR269A, a CAR T cell therapy, for Fast Track review for the treatment of relapsed/refractory multiple myeloma ((MM)).The candidate is currently being evaluated in an open-label, parallel assignment, single-dose, dose-escalation and dose-expansion Phase 1/2a clinical trial in MM patients.Fast Track status provides for more...

Seeking Alpha | September 9, 2020

Why This FDA Update Is a Huge Step Forward for Precision BioSciences

No summary available.

24/7 Wall street | September 9, 2020

Precision BioSciences EPS misses by $0.05, misses on revenue

Precision BioSciences (DTIL): Q2 GAAP EPS of -$0.63 misses by $0.05.Revenue of $1.08M (-80.0% Y/Y) misses by $3.31M.Press Release...

Seeking Alpha | August 13, 2020

Will Precision BioSciences (NASDAQ:DTIL) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | July 17, 2020

Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program

Precision BioSciences, Inc. (DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that the Company will regain full rights and all data it generated for the in vivo chronic hepatitis B virus (HBV) program developed under its 2018 collaboration agreement with Gilead Sciences. “This was a highly productive and well-aligned collaboration, and we deeply value the opportunity to advance our ARCUS genome editing technology and a potential cure for HBV alongside a global leader in infectious disease,” commented Derek Jantz, Ph.D., Chief Scientific Officer, Precision BioSciences.

Yahoo | July 6, 2020

Read More 'DTIL' Stories Here

DTIL Price Returns

1-mo -0.46%
3-mo -7.99%
6-mo -0.46%
1-year -0.46%
3-year N/A
5-year N/A
YTD -53.56%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.678 seconds.